Heron Therapeutics, Inc. (HRTX) has entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals, LLC, effective September 23, 2026. The agreement grants Heron an exclusive license to commercialize certain products in the United States and a non-exclusive license to manufacture them for sale in the territory.
Key Details
- License Terms: Heron receives an exclusive license to import, distribute, sell, and market the products in the U.S. and a non-exclusive, worldwide license to manufacture the products for sale in the U.S.
- Financial Obligations: In exchange for the rights, Heron will make undisclosed regulatory milestone payments, sales-based milestone payments, and royalty payments to Long Grove.
- Agreement Duration: The agreement has an initial term of ten (10) years following the first commercial sale of a licensed product, with automatic two-year renewal terms thereafter.